EGFR-IN-46 是一种有效的EGFR和FAK双重抑制剂，IC50s 分别为 20.17 nM，14.25 nM。EGFR-IN-46 显著抑制癌细胞的生长。EGFR-IN-46 诱导细胞凋亡 (Apoptosis)sup>[1]。

EGFR-IN-46 is a potent EGFR and FAK dual inhibitor with IC 50 s of 20.17 nM, 14.25 nM, respectively. EGFR-IN-46 significantly inhibits the growth of cancer cells. EGFR-IN-46 induces cell apoptosis [1].

EGFR-IN-46 (compound 6h) (0-100 μM; 24 h) inhibits the growth activity against DLD1, HCT-116 cells with IC 50 s of 1.79, 3.28 μM, respectively [1]. EGFR-IN-46 (3 μM; 24 h) induces cell apoptosis in DLD1 cells [1]. EGFR-IN-46 exhibits weak TOP1 (Topoisomerase I) poisoning effect (-/+) [1]. Cell Proliferation Assay [1] Cell Line: DLD1, HCT-116, MDMBA-231, MCF-7, Hela cells Concentration: 10 μM Incubation Time: 24 h Result: Showed excellent growth inhibition with the percent growth inhibition of 92.36%, 89.34%, 84.76%, 90.36%, 90.78% for DLD1, HCT-116, MDMBA-231, MCF-7, Hela cells, respectively. Apoptosis Analysis [1] Cell Line: DLD1 cells Concentration: 3 μM Incubation Time: 24 h Result: Increased the total percentage of apoptotic cells from 7% to 90.33%.

2764772-88-3

C27H32F3N3O3

503.56

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years